Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer's Finerenone Stacks Up More CV Benefit Data Ahead Of Potential Approval

Executive Summary

The FIGARO-DKD cardiovascular outcomes trial showed finerenone reduced composite risk of CV death or non-fatal events in CKD patients with Type 2 diabetes, including earlier-stage patients.

You may also be interested in...



Bayer Backs Kerendia To Be A Blockbuster

Just approved In US for chronic kidney disease in patients with type 2 diabetes, Kerendia is going to be an important new treatment option, according to Bayer pharma head Stefan Oelrich, who was speaking as the Leverkusen-headquartered group unveiled a decent set of sales figures for the second quarter.

Bayer Focusing On Early CKD Testing In Kerendia US Launch

The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.

Japan Helps Bayer’s Eylea Sales To Sparkle

Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144332

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel